Highest Rated Comments
redd1t0r1 karma
Exposing regulatory capture… Is this a viable strategy for direct investigation, or contingent upon insiders coming forward? I’m especially concerned about “outrageous government conduct” in the FDA (complicit with the CDC) re: withholding info on fatalities associated with pharmaceuticals. I’ve discovered international court cases where privatizing these stats was upheld as privileged information. That is, commercial interests of pharmaceutical companies trump the public’s right to know. Oddly, the FDA itself acknowledges a landmark metastudy revealing 100,000 annual deaths (in U.S. hospital patients alone) from taking medications as prescribed. See: Lazarou J et al. JAMA 1998;279(15):1200–1205, cited @ www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm114848.htm
redd1t0r4 karma
Thanks for doing this AMA! Your website is enlightening & informative. ‘Appreciate the link.
Before looking over the info you’ve shared on the site, my impression was that most who had bad experiences either (1) failed to investigate their mover’s policies & procedures and/or (2) navigated the transaction based on their presumptions of what’s “fair” rather than reading/ clarifying the stipulations of their contract.
Even then, it can be a hard lesson to learn that verbal statements of policy aren’t contractual, and laws/regulations aren’t explained in contracts.
The information you provide makes it plain there are various hidden dimensions and contingencies of the moving transaction that aren’t revealed without special knowledge. Is much of what you cover in the text of your site revealed in the FMCSA booklet mentioned under “Extra Tips”?
View HistoryShare Link